These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14739735)

  • 1. Barriers to the use of warfarin: potential solutions.
    McAnulty JH
    J Interv Card Electrophysiol; 2004; 10 Suppl 1():17-20. PubMed ID: 14739735
    [No Abstract]   [Full Text] [Related]  

  • 2. [Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].
    Steurer J
    Praxis (Bern 1994); 2014 Jun; 103(13):785-6. PubMed ID: 24938162
    [No Abstract]   [Full Text] [Related]  

  • 3. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues.
    Eckman MH; Levine HJ; Salem DN; Pauker SG
    Chest; 1998 Nov; 114(5 Suppl):699S-714S. PubMed ID: 9822072
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality of anticoagulation control in atrial fibrillation.
    Lane DA; Lip GY
    Lancet; 2010 Sep; 376(9745):935-7. PubMed ID: 20801499
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
    Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
    Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

  • 7. Aniticoagulation in patients following prosthetic heart valve replacement.
    Akhtar RP; Abid AR; Zafar H; Khan JS
    Ann Thorac Cardiovasc Surg; 2009 Feb; 15(1):10-7. PubMed ID: 19262444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation.
    Jaffer IH; Stafford AR; Fredenburgh JC; Whitlock RP; Chan NC; Weitz JI
    J Am Heart Assoc; 2015 Aug; 4(8):e002322. PubMed ID: 26304938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of ischemic stroke and hemorrhagic complications in warfarinized patients with non-valvular atrial fibrillation.
    Uchiyama S
    Intern Med; 2001 Dec; 40(12):1166-7. PubMed ID: 11813834
    [No Abstract]   [Full Text] [Related]  

  • 10. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why is warfarin underutilized in patients with atrial fibrillation?
    Flaker GC; Schutz J
    J Interv Card Electrophysiol; 2004; 10 Suppl 1():21-5. PubMed ID: 14739736
    [No Abstract]   [Full Text] [Related]  

  • 13. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
    Bratland B; Hornnes MB
    Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?
    DeCara JM; Croze S; Falk RH
    Chest; 1998 Feb; 113(2):261-3. PubMed ID: 9498932
    [No Abstract]   [Full Text] [Related]  

  • 15. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Edwards DB; Silverberg J
    Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502658
    [No Abstract]   [Full Text] [Related]  

  • 16. New anticoagulants offer options beyond warfarin to reduce stroke risk.
    Mitka M
    JAMA; 2012 Nov; 308(17):1727-8. PubMed ID: 23117757
    [No Abstract]   [Full Text] [Related]  

  • 17. Warfarin--indications, risks and drug interactions.
    Tadros R; Shakib S
    Aust Fam Physician; 2010 Jul; 39(7):476-9. PubMed ID: 20628660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The direct thrombin inhibitor melagatran/ximelagatran.
    Bereznicki LR; Jackson SL; Peterson GM
    Med J Aust; 2005 Mar; 182(5):254-5. PubMed ID: 15748144
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.